ACXP vs. INDP, AYTU, SGMT, CNTX, RNAC, PRQR, INCR, RZLT, CYBN, and RAPT
Should you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Indaptus Therapeutics (INDP), Aytu BioPharma (AYTU), Sagimet Biosciences (SGMT), Context Therapeutics (CNTX), Cartesian Therapeutics (RNAC), ProQR Therapeutics (PRQR), InterCure (INCR), Rezolute (RZLT), Cybin (CYBN), and RAPT Therapeutics (RAPT). These companies are all part of the "pharmaceutical preparations" industry.
Indaptus Therapeutics (NASDAQ:INDP) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk.
Indaptus Therapeutics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.79, suggesting that its stock price is 279% less volatile than the S&P 500.
7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 29.5% of Indaptus Therapeutics shares are held by insiders. Comparatively, 35.3% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Acurx Pharmaceuticals' return on equity of -108.14% beat Indaptus Therapeutics' return on equity.
Indaptus Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 334.78%. Acurx Pharmaceuticals has a consensus price target of $12.00, suggesting a potential upside of 380.00%. Given Indaptus Therapeutics' higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Indaptus Therapeutics.
Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Acurx Pharmaceuticals received 1 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. Likewise, 91.67% of users gave Acurx Pharmaceuticals an outperform vote while only 83.33% of users gave Indaptus Therapeutics an outperform vote.
In the previous week, Indaptus Therapeutics had 2 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 4 mentions for Indaptus Therapeutics and 2 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 1.53 beat Indaptus Therapeutics' score of 0.92 indicating that Indaptus Therapeutics is being referred to more favorably in the media.
Summary
Acurx Pharmaceuticals beats Indaptus Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Acurx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acurx Pharmaceuticals Competitors List
Related Companies and Tools
